ArticleToxics2026
Lentinan Improves Sodium Arsenite-Induced Hepatic Lipid Accumulation and Ferroptosis: Role of AMPK Signaling Pathway.
Article in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sodium arsenite (SA) is an environmental chemical toxin that induces hepatotoxicity and cellular ferroptosis under exposure. Ferroptosis is characterized by elevated ferrous ion levels and decreased glutathione peroxidase 4 (GPX4) activity. Lentinan (LNT), a bioactive polysaccharide derived from shiitake mushrooms, was investigated for its regulatory effects on SA-induced hepatotoxicity. In vivo experiments demonstrated that LNT ameliorated SA-induced hepatic lipid accumulation, increased GPX4 content and the mRNA levels of AMP-activated protein kinase (AMPK), and decreased ferrous ion concentrations in the livers of mice. However, co-administration of the AMPK inhibitor compound C and LNT negated these protective effects on hepatic lipid accumulation and ferroptosis-related markers. Complementary in vitro studies revealed that LNT activates AMPK signaling, mimicking the antagonistic effects of the AMPK agonist metformin (Met) on lipid accumulation and ferroptosis in hepatocytes exposed to SA. Notably, immunoblotting analyses indicated that treatment with LNT or Met increased the LC3-II/LC3-I ratio and upregulated the expression of ULK1 and the lipophagy receptor oxysterol-binding protein-related protein 8 (ORP8). Furthermore, co-immunoprecipitation assays demonstrated enhanced interaction between ORP8 and ULK1, suggesting activation of the AMPK-mediated ORP8/ULK1 signaling pathway. This pathway appears to play a protective role against SA-induced hepatic lipid accumulation and ferroptosis. Collectively, these findings elucidate the beneficial effects of LNT-mediated AMPK activation in mitigating SA-induced lipid accumulation and ferroptosis in the liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.